In early June, the first case of monkeypox (now known as MPX) was identified in San Francisco, and as of November 2, 2022, a total of 833 cases have been identified in SF. There has been a notable decline in MPX case counts, and now over 27,000 San Franciscans have been vaccinated against MPX. In response, the SFDPH ended the public health emergency on MPX on October 31, 2022. Despite the drastic decline in MPX cases since the peak of the outbreak in August 2022, MPX has not been eradicated and we must remain vigilant to prevent future outbreaks. We request that clinicians:

- Maintain clinical suspicion for MPX when seeing a patient with new rash or lesions characteristic of MPX
- Test patients with symptoms suspicious for MPX
- Continue to offer vaccine to ALL eligible patients. The most up to date MPX vaccine eligibility criteria are here, which includes gay or bisexual men, or any man, trans or nonbinary person who has sex with men, trans or nonbinary people; sex workers of any sexual orientation or gender identity; all persons living with HIV; and all persons who are taking or are eligible to take PrEP
- Ensure that patients receive BOTH DOSES of the 2-dose Jynneos vaccine series. The MPX vaccine is most effective when administered as a series of 2 injections at least 4 weeks apart.
- Provide the option for subcutaneous vaccine administration. Preliminary evidence suggests patients are hesitant to receive the vaccine intradermally due to concerns of a localized injection site reaction and/or potential stigma. CDC and CDPH are now allowing flexibility with route of vaccine administration in response to these concerns and the increasing vaccination supply.

While the MPX emergency response has ended, you can continue to find updated MPX guidance for SF providers at www.sfcdc.org/monkeypoxHCP, including information on testing, treatment, and patient education.

Provider STI Reporting: 628-217-6653, 628-217-6603 (fax)